IP Library › Granted Patent US 12,258,590
Granted Patent B2
US 12,258,590 · App. 18/386,621 · Granted Mar 25, 2025

Mutant Taq polymerase providing faster amplification

Inventors: Zhenyu Zhu (Lynnfield, MA); Dapeng Sun (Lexington, MA)
Assignee: ABCLONAL SCIENCE, INC.
C12N9/1252C12N9/12C12N15/63C12Q1/686C12Q2521/10C12Q2527/101C12Q2533/101
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,590
App. No.
18/386,621
Granted
Mar 25, 2025
Kind
B2
Abstract

The invention includes a mutant Taq polymerase, which can significantly extend and amplify a target sequence where the extension conditions are time limited to as little as one second. The mutant Taq polymerase, or a biologically active fragment thereof, has one or more substitutions differing from the wild type as shown in Table I.

Claims (5)

1. A mutant Taq polymerase comprising: the following amino acid mutations shown in the following even-numbered sequences, and wherein the remainder of the mutant polymerase has at least 80% amino acid sequence identity with wild type Taq polymerase, as shown in SEQ ID NO: 4, but not including the 6-membered histidine tag at its C-terminus and the six immediately preceding Glycine and Serine amino acids shown in SEQ ID NO: 4:

E189L (SEQ ID NOS: 102-103), E189M (SEQ ID NOS: 104-105), E189P (SEQ ID NOS: 106-107), E189Q (SEQ ID NOS: 108-109), E189R (SEQ ID NOS: 110-111), E189T (SEQ ID NOS: 112-113), E189W (SEQ ID NOS: 114-115), E201K (SEQ ID NOS: 116-117), E230C (SEQ ID NOS: 122-123), E230F (SEQ ID NOS: 124-125), E230H (SEQ ID NOS: 126-127), E230K/E520K (SEQ ID NOS: 132-133), E230K/E537K (SEQ ID NOS: 134-135), E230K/D578R (SEQ ID NOS: 136-137), and E230K/D732R (SEQ ID NOS: 138-139).

2. The mutant Taq polymerase of claim 1 wherein the remainder of the mutant polymerase has at least 95% amino acid sequence identity with wild type Taq polymerase.

3. The mutant Taq polymerase of claim 1 wherein the remainder of the mutant polymerase has at least 99% amino acid sequence identity with wild type Taq polymerase.

4. The mutant Taq polymerase of claim 1 wherein the remainder of the mutant polymerase has 100% amino acid sequence identity to SEQ ID NO: 4.

Continuity (4)
Continuation 17106804 · Nov 30, 2020
Continuation 16813425 · Mar 9, 2020
Provisional Application 62818011 · Mar 13, 2019
Related Publication 20240124854A1 · Apr 18, 2024
References Cited (11)
US 5108892A · Burke et al. · 1992 [cited by applicant]
US 7045289B2 · Allawi et al. · 2006 [cited by applicant]
US 9315787B2 · Schafer et al. · 2016 [cited by applicant]
US 20110281305A1 · Bourn · 2011 [cited by examiner]
WO WO2005083068 · 2005 [cited by applicant]
WO WO2010062777 · 2010 [cited by applicant]
WO WO2013177429 · 2013 [cited by applicant]
WO WO2018096961 · 2018 [cited by applicant]
Yamagami, T., et al., “Mutant Taq DNA po1ymerases with improved elongation ability as a useful reagent for genetic engineering.” Frontiers in Microbiology. 5:461. 1-10.7. [cited by applicant]
Order Granting Request For Ex Parte Reexamination Aug. 9, 2024. [cited by applicant]
Request for Ex Parte Reexamination of U.S. Pat. No. 10,865,441 Jun. 20, 2024. [cited by applicant]